{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-071272","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.918458+00:00","generated_at":"2026-06-11T02:54:50.074284+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bluejay Diagnostics announces $1.59M registered direct offering and warrant private placement","bullets":["Company entered definitive agreement for registered direct offering of 216,000 shares at $7.365/share, raising ~$1.59M gross.","Concurrent private placement of warrants to purchase 216,000 shares at $7.24/share, exercisable for 5 years.","Proceeds intended for FDA approval activities, clinical studies, R&D, and general working capital.","H.C. Wainwright & Co. acted as exclusive placement agent; closing expected August 28, 2023.","Warrants and underlying shares sold unregistered under Section 4(a)(2) and Regulation D."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-071272","json":"https://secwatch.observer/filing/0001213900-23-071272.json","markdown":"https://secwatch.observer/filing/0001213900-23-071272.md","text":"https://secwatch.observer/filing/0001213900-23-071272.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/0001213900-23-071272-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/ea184305-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:54:50.074284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9dbfd6e2f01f55fef699524c4bdedd30bdc24852","claim":"Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.59 million (effective 2023-08-24).","evidence_excerpt":"On August 24, 2023, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 216,000 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023071272/0001213900-23-071272-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $1.59 million"},{"label":"Effective","value":"2023-08-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}